The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Double Blind Randomized Trial of Cediranib versus placebo in patients receiving Paclitaxel/Carboplatin Chemotherapy for the treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
- collapse A randomised placebo-controlled trial of concurrent cediranib [ZD2171] (with platinum-based chemotherapy) and concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer.
- collapse This group of 20 plus NCI studies does not have a protocol title.
- collapse Phase 1, Open-Label, Dose-Seeking Study of AZD2171 given daily orally in combination with standard chemotherapy regimens in patients with advanced incurable non-small cell lung cancer or colorectal cancer
- collapse Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients with Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response
- collapse Faslodex Post Marketing Surveillance
- collapse A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Malignancies
- collapse A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy and in Combination with Paclitaxel in Japanese Patients with Advanced Solid Malignancies
- collapse Protocol for the specified clinical experience investigation on the single use of Casodex Tablet 80 mg
- collapse A retrospective, medical record study to investigate the current situation of biopsy testing in the Swedish inoperable Non Small Cell Lung Cancer patient population.
